Hologic
Corporate brand
UnclaimedA medical technology company focused primarily on women's health, including diagnostics, breast imaging, and minimally invasive surgery.
Last updated August 21, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Hologic is a United States-based medical technology company whose business is centered on women's health. Its portfolio spans diagnostic testing, breast and skeletal health imaging, gynecological surgery, and related medical devices. The company serves hospitals, outpatient clinics, imaging centers, laboratories, physicians, and health systems rather than operating primarily as a consumer healthcare brand. Hologic's best-known activities are in breast health and molecular diagnostics. Its breast-health portfolio includes digital mammography and three-dimensional breast tomosynthesis systems, image-guided biopsy equipment, and technologies used in the diagnosis and management of breast disease. The company has marketed 3D mammography systems under the Genius and 3Dimensions families, positioning these products around improved visualization, screening workflow, and early detection support. Its diagnostic business includes the Aptima molecular testing platform and assays used in areas such as sexually transmitted infections, respiratory disease, viral load monitoring, and other laboratory applications. During the COVID-19 pandemic, Hologic expanded its molecular-testing role through emergency-authorized SARS-CoV-2 assays and government-supported manufacturing expansion. The company substantially broadened its women's-health scope through acquisitions. The 2007 purchase of Cytyc added the ThinPrep cervical cancer screening franchise and NovaSure endometrial ablation technology, strengthening Hologic's position in gynecological diagnostics and treatment. Later transactions added breast cancer testing, surgical localization products, multiplex molecular diagnostics, and technology for uterine fibroids. Hologic also entered aesthetic medicine through its 2017 acquisition of Cynosure, but divested that business in 2019 to concentrate more closely on its core medical technology activities. Hologic's products are primarily sold through professional and institutional channels. Its positioning combines clinical specialization, recurring laboratory diagnostics, procedure-based medical devices, and capital equipment for imaging providers. This mix gives the company exposure to screening programs, laboratory testing volumes, surgical procedures, and long-term equipment placements. The brand's public identity is closely associated with women's health innovation, breast cancer screening, cervical cancer prevention, reproductive health, and diagnostic access. The company has also used partnerships and sponsorships to raise awareness of women's health. In 2022, Hologic became title sponsor and official health partner of the Women's Tennis Association tour, linking the corporate brand with women's health advocacy and elite women's sport. Hologic remained a publicly listed company for much of its documented history under the HOLX ticker. Reference material states that Blackstone and TPG agreed in 2025 to acquire the company in a transaction valued at approximately $18.3 billion including debt, with completion described as occurring in 2026; the ownership and operating status should therefore be verified against current corporate and regulatory filings.
History
Hologic was established in 1985 in the United States as a medical technology company focused on women's health. Its development has been shaped by the combination of internally developed imaging and diagnostic technologies with a series of acquisitions that expanded its reach across screening, laboratory medicine, and gynecological procedures. A major turning point came in 2007, when Hologic completed its acquisition of Cytyc in a cash-and-stock transaction valued at approximately $6.2 billion. Cytyc contributed the ThinPrep Pap test, a widely used cervical cancer screening product, together with NovaSure endometrial ablation technology and related capabilities. The transaction moved Hologic beyond breast imaging and strengthened its position in cervical cancer prevention, gynecological diagnostics, and minimally invasive treatment. The company attracted activist-investor attention in late 2013, when Carl Icahn disclosed a 12.5 percent interest. Hologic adopted a shareholder-rights plan intended to deter an unsolicited takeover. Following discussions with the board, two directors supported by Icahn joined the board. Those directors later resigned in March 2016, and Icahn exited his investment by May of that year. The episode became an important governance event but did not change Hologic's core medical technology orientation. In 2017, Hologic acquired Cynosure, an aesthetic medicine company based in Massachusetts, for approximately $1.65 billion. The deal temporarily broadened the portfolio beyond women's health and medical diagnostics. Hologic subsequently reassessed that strategy and announced Cynosure's sale to Clayton, Dubilier & Rice in 2019 for approximately $205 million. The divestiture closed at the end of that year and returned the company to a more concentrated healthcare profile. The COVID-19 pandemic created a new role for Hologic's molecular diagnostics business. In March 2020, the company obtained U.S. emergency authorization for a SARS-CoV-2 test, followed by a second authorization in May intended to expand potential throughput. Hologic also collaborated with Grifols to increase testing capacity in Spain. In November 2020, the U.S. government awarded the company a $119 million contract to expand production facilities in Wisconsin, Maine, and California, with the stated objective of reaching production capacity of 13 million COVID-19 tests per month by January 2022. Hologic continued to build its diagnostic and surgical portfolio through acquisitions in 2021. Biotheranostics added breast and metastatic cancer test products, while SOMATEX added devices used in breast procedures. Hologic then agreed to acquire Mobidiag, a molecular diagnostics company with multiplex testing technology; the transaction was completed in June 2021. These moves reinforced the company's combination of laboratory testing, oncology-related diagnostics, and procedure-support products. Brand-building outside the clinical marketplace became more visible in 2022, when Hologic became title sponsor and official health partner of the Women's Tennis Association tour. The partnership connected the company with women's sport and public discussion of women's health. In 2024, Hologic agreed to acquire Endomag, a British medical device manufacturer, for approximately $310 million; completion was reported in July. In 2025, it acquired Gynesonics for approximately $350 million, adding the Sonata system for ultrasound-guided treatment of uterine fibroids. Reference material further states that Blackstone and TPG announced an agreement in October 2025 to acquire Hologic for approximately $18.3 billion including debt, with the transaction described as taking the company private in 2026. Because this timing extends beyond some currently available corporate records, the final ownership, listing status, and completion date require verification from current filings and official company disclosures.
- 2025
Gynesonics acquired
[1]Hologic adds the Sonata system for ultrasound-guided treatment of uterine fibroids.
- 2024
Endomag acquisition completed
[1]The acquisition adds British breast surgery and localization technology.
- 2022
WTA partnership begins
[1]Hologic becomes title sponsor and official health partner of the Women's Tennis Association tour.
- 2021
Diagnostic portfolio acquisitions
[1]Biotheranostics, SOMATEX, and Mobidiag expand Hologic's cancer testing, surgical localization, and multiplex diagnostics capabilities.
- 2020
COVID-19 testing expansion
[1]Emergency-authorized SARS-CoV-2 assays and a U.S. government manufacturing contract expand Hologic's pandemic testing role.
- 2017
Cynosure acquired
[1]Hologic enters aesthetic medicine through the purchase of Cynosure.
- 2007
Cytyc acquisition completed
[1]The acquisition adds ThinPrep cervical screening and NovaSure endometrial ablation to Hologic's portfolio.
- 1985
Hologic is founded
[1]Hologic begins operations as a U.S. medical technology company focused on women's health.
Products and positioning
A specialist medical technology company focused on improving women's health through screening, diagnosis, imaging, and minimally invasive treatment.
Breast imaging
3Dimensions
A digital breast tomosynthesis and mammography system used by breast-imaging providers for screening and diagnostic examinations. The platform is designed for three-dimensional breast imaging, workflow integration, and image review in clinical settings.
Molecular diagnostics
Aptima
A molecular diagnostics platform and family of assays used in laboratory testing. Its applications include infectious-disease and sexually transmitted infection testing, as well as other molecular workflows performed by clinical laboratories.
Cervical cancer screening
ThinPrep Pap test
A liquid-based cervical cytology test obtained through the Cytyc acquisition. It is used as part of cervical cancer screening and has been a foundational product in Hologic's gynecological diagnostics business.
Gynecological surgery
NovaSure
An endometrial ablation technology used to treat heavy menstrual bleeding by removing or ablating the uterine lining. The product entered Hologic's portfolio through the Cytyc acquisition.
Uterine fibroid treatment
Sonata System
An ultrasound-guided system developed by Gynesonics for transcervical treatment of uterine fibroids. Hologic added the technology through its 2025 acquisition of Gynesonics.
Marketing campaigns
- 2022Hologic WTA partnership
Global
Hologic became title sponsor and official health partner of the Women's Tennis Association tour, using women's professional tennis as a platform for visibility around women's health.
Outcome. Established a prominent global sports and health partnership.
Brand decisions
2025
Agree to acquisition by Blackstone and TPGM&ABackground
Reference material describes a proposed take-private transaction involving the publicly listed medical technology company.
Action taken
Blackstone and TPG agreed to acquire Hologic for approximately $18.3 billion including debt.
Aftermath
The transaction was described as completing in 2026; current ownership and listing status require verification.
Enterprise transaction value. $18.3 billion approximately including debt (Announced October 2025; completion described as 2026)
2020
Expand SARS-CoV-2 testingProduct launchBackground
The COVID-19 pandemic created urgent demand for high-throughput molecular testing.
Action taken
Obtained emergency authorizations for SARS-CoV-2 tests and expanded manufacturing with U.S. government support.
Aftermath
Hologic became a significant contributor to pandemic testing capacity in the United States and selected international markets.
U.S. government contract. $119 million (November 2020)
2019
Divest CynosureStrategyBackground
Hologic decided to reduce exposure to aesthetic medicine and concentrate on its principal healthcare businesses.
Action taken
Agreed to sell Cynosure to Clayton, Dubilier & Rice.
Aftermath
The sale closed in December 2019 for approximately $205 million.
Divestiture proceeds. $205 million approximately (2019)
2017
Acquire CynosureM&ABackground
Hologic expanded into aesthetic medicine.
Action taken
Purchased Cynosure for approximately $1.65 billion.
Aftermath
The company later divested Cynosure in 2019 to refocus on core medical technology.
Acquisition price. $1.65 billion approximately (2017)
2007
Acquire CytycM&ABackground
Hologic sought to expand its women's-health diagnostics and treatment portfolio.
Action taken
Completed a cash-and-stock acquisition valued at approximately $6.2 billion.
Aftermath
Hologic added ThinPrep, NovaSure, and related gynecological capabilities.
Transaction value. $6.2 billion approximately (2007)
Recent events
Reported
Hologic becomes global title sponsor of the WTA Tour[3]
Hologic and the WTA announced a multi-year partnership naming Hologic the global title sponsor of the WTA Tour and its official health partner.
Reported
Hologic announces national advertising campaign[4]
Hologic announced a national direct-to-consumer advertising campaign featuring Mary J. Blige. The campaign was scheduled to begin with a television spot during the February 13, 2022 Big Game and continue through the Winter Olympics.
Reported
OWN YOUR HEALTH and Hologic announce partnership[5]
Oprah Winfrey Network's OWN YOUR HEALTH initiative and Hologic's Project Health Equality announced an exclusive partnership to raise awareness of healthcare disparities affecting Black women, provide education and preventive tools, and share original content.
Reported
Hologic announces acquisition of Mobidiag[6]
Hologic announced that it had agreed to acquire Mobidiag Oy for $795 million, including $714 million in cash for its equity and approximately $81 million in net debt.
Reported
Hologic and Gallup partner to develop Women’s Health Index[7]
Hologic announced that it is teaming up with Gallup to develop the Hologic Women’s Health Index. The article reports that the two had begun collaborating on the survey in 2019.
Reported
Hologic completes acquisition of Biotheranostics[8]
Hologic completed its previously announced acquisition of Biotheranostics for approximately $230 million.
Reported
Hologic and Google Cloud announce diagnostics partnership[9]
Hologic announced a multi-year partnership with Google Cloud to integrate Google Cloud machine-learning technologies into Hologic’s Genius Digital Diagnostics system, which helps doctors screen for cervical cancer.
Reported
Hologic partners with RAD-AID on screening and diagnostic services[10]
Hologic announced a partnership with RAD-AID under which Hologic will fund breast-cancer screening and diagnostic services and support a pathway to treatment for medically disenfranchised women.
Reported
Hologic partners with BWHI and RAD-AID on breast screening initiative[11]
Hologic announced a multi-year initiative with the Black Women’s Health Imperative and RAD-AID to address breast cancer screening disparities for Black women, including an awareness campaign and funding for screening and diagnostic services.
Reported
Hologic launches Back to Screening campaign[12]
Hologic launched its Back to Screening campaign, encouraging women to schedule annual mammograms as healthcare facilities reopened. The campaign included an appointment-reminder page and a sweepstakes for a private virtual performance.
Sources13 sources
- 1Hologicen.wikipedia.org
- 2Hologic official websitehologic.com
- 3Hologic成为WTA巡回赛全球冠名赞助商en.antaranews.com
- 4Hologic宣布全国广告活动itnonline.com
- 5OWN YOUR HEALTH与Hologic宣布合作itnonline.com
- 6Hologic宣布收购Mobidiagwbjournal.com
- 7Hologic与Gallup合作开发女性健康指数wbjournal.com
- 8Hologic完成收购Biotheranosticsitnonline.com
- 9Hologic 与 Google Cloud 宣布诊断技术合作wbjournal.com
- 10Hologic与RAD-AID合作提供筛查和诊断服务prnewswire.com
- 11Hologic 与 BWHI 和 RAD-AID 合作开展乳腺筛查计划itnonline.com
- 12Hologic推出“重返筛查”宣传活动itnonline.com
- 13FDA批准Hologic 3DQuorum成像技术wbjournal.com
Cite this profile: Cite the canonical profile. /brand-wiki/hologic · Editorial policy · How profiles are compiled